 |
|
Obesity, Weight Change, Hypertension, Diuretic Use, and Risk of Gout in Men
The Health Professionals Follow-up Study
Hyon K. Choi, MD, DrPH;
Karen Atkinson, MD, MPH;
Elizabeth W. Karlson, MD;
Gary Curhan, MD, ScD
Arch Intern Med. 2005;165:742-748.
Background Limited prospective information exists on the relation between obesity and weight change and the risk of gout. Similarly, both hypertension and diuretic use have been considered risk factors for gout; however, their independent contributions have not been established prospectively.
Methods We prospectively examined over a 12-year period (1986-1998) the relation between adiposity, weight change, hypertension, and diuretic use and incident gout in 47 150 male participants with no history of gout at baseline. We used a supplementary questionnaire to ascertain the American College of Rheumatology criteria for gout.
Results During 12 years we documented 730 confirmed incident cases of gout. Compared with men with a body mass index (BMI) of 21 to 22.9, the multivariate relative risks (RRs) of gout were 1.95 (95% confidence interval [CI], 1.44-2.65) for men with a BMI of 25 to 29.9, 2.33 (95% CI, 1.62-3.36) for men with a BMI of 30 to 34.9, and 2.97 (95% CI, 1.73-5.10) for men with a BMI of 35 or greater (P for trend <.001). Compared with men who had maintained their weight (±4 lb) since age 21 years, the multivariate RR of gout for men who had gained 30 lb or more since age 21 years was 1.99 (95% CI, 1.49-2.66). In contrast, the multivariate RR for men who had lost 10 lb or more since the study baseline was 0.61 (95% CI, 0.40-0.92). The multivariate RRs of gout were 2.31 (95% CI, 1.96-2.72) for the presence of hypertension and 1.77 (95% CI, 1.42-2.20) for diuretic use.
Conclusions Higher adiposity and weight gain are strong risk factors for gout in men, while weight loss is protective. Hypertension and diuretic use are also important independent risk factors for gout.
Author Affiliations: Rheumatology Unit, Department of Medicine, Massachusetts General Hospital (Drs Choi and Atkinson), and Division of Rheumatology (Dr Karlson) and Channing Laboratory (Dr Curhan), Brigham and Women’s Hospital, Harvard Medical School; and Department of Epidemiology, Harvard School of Public Health (Drs Choi and Curhan); Boston, Mass.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study
Choi and Curhan
BMJ 2008;336:309-312.
ABSTRACT
| FULL TEXT
Gout Affecting the Hand and Wrist
Fitzgerald et al.
J Am Acad Orthop Surg 2007;15:625-635.
ABSTRACT
| FULL TEXT
Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations
Roddy et al.
Ann Rheum Dis 2007;66:1311-1315.
ABSTRACT
| FULL TEXT
Independent Impact of Gout on Mortality and Risk for Coronary Heart Disease
Choi and Curhan
Circulation 2007;116:894-900.
ABSTRACT
| FULL TEXT
Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout
Willburger et al.
Rheumatology (Oxford) 2007;46:1126-1132.
ABSTRACT
| FULL TEXT
Sex differences in gout epidemiology: evaluation and treatment
Harrold et al.
Ann Rheum Dis 2006;65:1368-1372.
ABSTRACT
| FULL TEXT
High Urinary Calcium Excretion and Genetic Susceptibility to Hypertension and Kidney Stone Disease
Mente et al.
J. Am. Soc. Nephrol. 2006;17:2567-2575.
ABSTRACT
| FULL TEXT
Gout, diuretics and the kidney.
Pascual and Perdiguero
Ann Rheum Dis 2006;65:981-982.
FULL TEXT
Diagnosis and management of gout.
Underwood
BMJ 2006;332:1315-1319.
FULL TEXT
Pathogenesis of Gout
Choi et al.
ANN INTERN MED 2005;143:499-516.
FULL TEXT
|
